Through targeted cytosolic release exemplified by Calix-STING supramolecular carriers, ligand-directed tumor homing via antibody conjugation, and synergistic codelivery of dual agonists in STING/TLR4 nanoliposomes, nanoplatforms establish transformative synergy with immune agonists and PD-1 inhibitors. This evidence concerns the gene PDCD1 and neoplasm.